Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762996 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| SCHEMBL7493133 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| Bromide SCHEMBL2424119 | 0.98 | CHRM2 (0.41) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2421080 | 0.98 | ALDH1A1 (0.45) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7498477 | 0.98 | ALDH1A1 (0.45) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| Bromide SCHEMBL9298859 | 0.98 | CHRM2 (0.41) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7499660 | 0.98 | ALDH1A1 (0.45) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7093326 | 0.98 | ALDH1A1 (0.45) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| SCHEMBL10368012 | 0.98 | CHRM2 (0.45) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5139420 | 0.98 | ALDH1A1 (0.45) | CHRM2CHRM1CHRM4CHRM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0257741-A2 | Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-03-02 | — | — | EP | claimed |
| JP-3027355-A | — | — | None | — | — | JP | disclosed |
| JP-3063272-A | — | — | None | — | — | JP | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-10858367-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20130316945-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-28 | — | — | US | disclosed |
| US-8426359-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| EP-0398616-A2 | Chiral synthesis for producing 1-azabicyclo[2.2.1]heptane-3-carboxylates | MERCK SHARP & DOHME LTD. (GB) | 1990-11-22 | — | — | EP | disclosed |
| US-4968691-A | TREATMENT AND PREVENTION OF DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1990-11-06 | — | — | US | disclosed |
| EP-0392803-A1 | Novel compounds | Beecham Group p.l.c. (GB) | 1990-10-17 | — | — | EP | disclosed |
| EP-0375450-A2 | 3-(3-Ethyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo(2.2.1) heptane, process for its preparation and pharmaceutical compositions containing it | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0366304-A2 | Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-05-02 | — | — | EP | disclosed |
| EP-0338723-A1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1989-10-25 | — | — | EP | disclosed |
| US-4870081-A | DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1989-09-26 | — | — | US | disclosed |
| EP-0322182-A2 | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1989-06-28 | — | — | EP | disclosed |
| EP-0261763-A1 | Novel bridged bicyclic N-heterocycles | BEECHAM GROUP PLC (GB) | 1988-03-30 | — | — | EP | disclosed |
| EP-0257741-A2 | Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858367-B2 | Compounds | LRRK2, PARK7, PINK1 | CHRM2 2981/4885CHRM1 3217/4885CHRM4 3475/4885 |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CHRM2 4596/4885CHRM1 4752/4885CHRM4 4615/4885 |
| US-20130316945-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | CHRM2 4868/4885CHRM1 4815/4885CHRM4 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.